Amy Killelea, Natalie O. Cramer, and Michael Weir Comment

Am J Public Health. 2020 Jan;110(1):25-26. doi: 10.2105/AJPH.2019.305417.
No abstract available

Publication types

  • Editorial

MeSH terms

  • AIDS Vaccines / administration & dosage
  • Acquired Immunodeficiency Syndrome / prevention & control
  • Anti-Retroviral Agents / therapeutic use
  • Case Management / organization & administration
  • Diagnostic Techniques and Procedures
  • Epidemics / prevention & control*
  • Epidemics / statistics & numerical data*
  • Financing, Government
  • HIV Infections / diagnosis
  • HIV Infections / drug therapy
  • HIV Infections / epidemiology*
  • HIV Infections / prevention & control*
  • Humans
  • Leadership
  • Needle-Exchange Programs / organization & administration
  • Organizational Objectives
  • Pre-Exposure Prophylaxis / methods
  • United States / epidemiology
  • United States Dept. of Health and Human Services / economics
  • United States Dept. of Health and Human Services / organization & administration*

Substances

  • AIDS Vaccines
  • Anti-Retroviral Agents